3Cunningham Md D,Rao S,Starling N,et al.Randomized multieentre phaseⅢ study comparing capeeitabine with tluorouracil and 0xaliplatin with eisplatin in patients with advanced oesophagogastrie(OG)cancer:The REAL 2 trial[J].Proc Am Soe Clin Oncol,2006,24:4017a.
5Cvitkovic E. A historical perspective on oxaliplatin: rethinking the role of platinum compounds and learning from near misses [J] . Semin Oncol, 1998, 25 (2, Suppl 5): 1.
6Extra JM, Marty M, Brienza S, et al. Pharmaeokineties and safety profile on oxaliplatin [ J ] . Senin Oncol, 1998, 25 (2, Suppl 5): 13.
7Jin ML, Chen, Q, Cheng FQ, et al. Oxaliplatin (OXA) in combination with LV/5-FU in Chinese patients with advanced gastriccancer (AGC) [ J ] . Proc ASCO, 2002, 21 : 558.
8Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP) [J]. Br J Cancer, 2003, 89(3) :477-481.
9Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin [J]. Cancer, 2003, 97(9) : 2301-2307.
10Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute [J]. Ann Oncol, 2006,17(2) :259-261.
